{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:39:04Z","timestamp":1771591144235,"version":"3.50.1"},"reference-count":27,"publisher":"Becaris Publishing Limited","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Due to extensive treatment switching in the MAVORIC trial, lack of UK regulatory licence for the comparator, overall survival (OS) with mogamulizumab was compared with patients with previously treated advanced mycosis fungoides\/S\u00e9zary syndrome (MF\/SS) in real-world setting.\n            <jats:bold>Design, setting &amp; participants:<\/jats:bold>\n            Data were from the Hospital Episode Statistics database (all patients in NHS secondary care system in 2009\u20132019). Patients were selected according to trial inclusion criteria, then trial and HES samples were matched on selected variables with significant imbalance.\n            <jats:bold>Outcomes:<\/jats:bold>\n            The analysis indicated significant improvement in OS for mogamulizumab treatment compared with UK clinical practice (hazard ratio: 0.36, 95% CI: 0.24, 0.53).\n            <jats:bold>Conclusion:<\/jats:bold>\n            Results suggest an OS advantage for patients with advanced MF\/SS treated with mogamulizumab in MAVORIC trial compared with UK clinical practice.\n          <\/jats:p>","DOI":"10.57264\/cer-2023-0017","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T12:50:17Z","timestamp":1693313417000},"source":"Crossref","is-referenced-by-count":5,"title":["Overall survival in the UK in mycosis fungoides or S\u00e9zary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care"],"prefix":"10.57264","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3199-221X","authenticated-orcid":false,"given":"Neil","family":"Hawkins","sequence":"first","affiliation":[{"name":"Visible Analytics, Oxford, OX2 0DP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1236-1327","authenticated-orcid":false,"given":"Noemi","family":"Muszbek","sequence":"additional","affiliation":[{"name":"Visible Analytics, Oxford, OX2 0DP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4430-0262","authenticated-orcid":false,"given":"Rachel","family":"Evans","sequence":"additional","affiliation":[{"name":"Visible Analytics, Oxford, OX2 0DP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4303-3791","authenticated-orcid":false,"given":"Linda","family":"McNamara","sequence":"additional","affiliation":[{"name":"Kyowa Kirin, Payor Value and Patient Access, Marlow, SL7 1HZ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4773-4837","authenticated-orcid":false,"given":"Trefor","family":"Jones","sequence":"additional","affiliation":[{"name":"Kyowa Kirin, Payor Value and Patient Access, Marlow, SL7 1HZ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"10","key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/cncr.22252","article-title":"Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey","volume":"107","author":"Demierre MF","year":"2006","unstructured":"Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer 107(10), 2504\u20132511 (2006).","journal-title":"Cancer"},{"issue":"32","key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and S\u00e9zary Syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick JJ","year":"2015","unstructured":"Scarisbrick JJ, Prince HM, Vermeer MH Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and S\u00e9zary Syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J. Clin. Oncol. 33(32), 3766\u20133773 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"31","key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar NS","year":"2010","unstructured":"Agar NS, Wedgeworth E, Crichton S Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal. J. Clin. Oncol. 28(31), 4730\u20134739 (2010).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 Update 2017","volume":"77","author":"Trautinger F","year":"2017","unstructured":"Trautinger F, Eder J, Assaf C European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 Update 2017. Eur. J. Cancer 77, 57\u201374 (2017).","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bjd.16447","article-title":"\u201cIt's a traumatic illness, traumatic to witness\u201d: a qualitative study of the experiences of bereaved family caregivers of patients with cutaneous T-cell lymphoma","volume":"179","author":"Orlowska D","year":"2018","unstructured":"Orlowska D, Selman LE, Beynon T \u201cIt's a traumatic illness, traumatic to witness\u201d: a qualitative study of the experiences of bereaved family caregivers of patients with cutaneous T-cell lymphoma. Br. J. Dermatol. 179(4), 882\u2013888 (2018).","journal-title":"Br. J. Dermatol."},{"issue":"7","key":"e_1_3_5_8_2","first-page":"857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim YH","year":"2003","unstructured":"Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch. Dermatol. 139(7), 857\u2013866 (2003).","journal-title":"Arch. Dermatol."},{"issue":"18","key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009","volume":"18","author":"Talpur R","year":"2012","unstructured":"Talpur R, Singh L, Daulat S Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009. Clin. Cancer Res. 18(18), 5051\u20135060 (2012).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_5_10_2","unstructured":"Public Health England. National Cancer Registration and Analysis Services. Registration of Cutaneous T-Cell Lymphoma (CTCL) in England. http:\/\/www.ncin.org.uk\/view?rid=3275"},{"issue":"3","key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson D","year":"2019","unstructured":"Gilson D, Whittaker SJ, Child FJ British Association of Dermatologists and UK Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Brit. J. Dermatol. 180(3), 496\u2013526 (2019).","journal-title":"Brit. J. Dermatol."},{"key":"e_1_3_5_12_2","unstructured":"National Institute for Health and Care Excellence (NICE). Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma | Guidance [TA577] (2019). https:\/\/www.nice.org.uk\/guidance\/ta577\/documents\/html-content-3"},{"key":"e_1_3_5_13_2","unstructured":"National Institute for Health and Care Excellence. Mogamulizumab for previously treated mycosis fungoides and S\u00e9zary syndrome [TA754] | Guidance| NICE. https:\/\/www.nice.org.uk\/guidance\/ta754"},{"issue":"9","key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomized, controlled phase III trial","volume":"19","author":"Kim YH","year":"2018","unstructured":"Kim YH, Bagot M, Pinter-Brown L Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomized, controlled phase III trial. Lancet Oncol. 19(9), 1192\u20131204 (2018).","journal-title":"Lancet Oncol."},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2022-0070"},{"issue":"8","key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-06-2672","article-title":"Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma","volume":"13","author":"Mann BS","year":"2007","unstructured":"Mann BS, Johnson JR, He K Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin. Cancer Res. 13(8), 2318\u20132322 (2007).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_5_17_2","unstructured":"Food and Drug Administration (FDA). FDA approves mogamulizumab-kpkc for mycosis fungoides or S\u00e9zary syndrome. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-mogamulizumab-kpkc-mycosis-fungoides-or-sezary-syndrome"},{"key":"e_1_3_5_18_2","unstructured":"European Medicines Agency (EMA). Withdrawal assessment report for Vorinostat MSD 100 mg hard capsules (2009). https:\/\/www.ema.europa.eu\/en\/documents\/withdrawal-report\/withdrawal-assessment-report-vorinostat-msd_en.pdf"},{"key":"e_1_3_5_19_2","unstructured":"NHS Digital. Hospital Episode Statistics (HES). NHS Digital (2020). https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics"},{"key":"e_1_3_5_20_2","unstructured":"Phillippo DM Ades AE Dias S Palmer S Abrams KR Welton NJ. NICE DSU TECHNICAL SUPPORT DOCUMENT 18: population-adjusted indirect comparisons (MAIC and STC) \u2013 NICE Decision Support Unit (2016). http:\/\/nicedsu.org.uk\/technical-support-documents\/population-adjusted-indirect-comparisons-maic-and-stc\/"},{"key":"e_1_3_5_21_2","article-title":"Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis","author":"Kim YH","year":"2019","unstructured":"Kim YH, Ortiz-Romero PL, Pro B Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis. Internati. Con. Malig. Lymph. Hematolog. Oncol. (2019). https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2019.37.15_suppl.7539","journal-title":"Internati. Con. Malig. Lymph. Hematolog. Oncol."},{"issue":"10","key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch JE","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 28(10), 935\u2013945 (2010).","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch JE","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6), 940\u2013947 (2012).","journal-title":"Value Health"},{"key":"e_1_3_5_24_2","first-page":"57","article-title":"NICE DSU Technical Support Document 16: Adjusting survival time estimates in the presence of treatment switching","author":"Latimer NR","year":"2014","unstructured":"Latimer NR, Abrams KR. NICE DSU Technical Support Document 16: Adjusting survival time estimates in the presence of treatment switching. Dec. Supp. Unit, ScHARR. 57 (2014). https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/treatment-switching","journal-title":"Dec. Supp. Unit, ScHARR."},{"issue":"1","key":"e_1_3_5_25_2","doi-asserted-by":"crossref","first-page":"e032884","DOI":"10.1136\/bmjopen-2019-032884","article-title":"Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration","volume":"10","author":"Chan K","year":"2020","unstructured":"Chan K, Nam S, Evans B Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. BMJ Open 10(1), e032884 (2020).","journal-title":"BMJ Open"},{"key":"e_1_3_5_26_2","unstructured":"Innovative Medicines Initiative (IMI)  IMI1 Final Project Report Public Summary: incorporating real-life clinical data into drug development (GETREAL) (2017). https:\/\/www.imi.europa.eu\/sites\/default\/files\/uploads\/documents\/115546_GetReal_Final_Report.pdf"},{"key":"e_1_3_5_27_2","unstructured":"U.S. Food and Drug Administration (FDA). Framework for FDA's Real-World Evidence Program (2018). https:\/\/www.fda.gov\/media\/120060\/download"},{"issue":"3","key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2217\/fon-2020-0591","article-title":"Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes","volume":"17","author":"O'Donnell JC","year":"2021","unstructured":"O'Donnell JC, Le TK, Dobrin R Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes. Future Oncol. 17(3), 333\u2013347 (2021).","journal-title":"Future Oncol."},{"key":"e_1_3_5_29_2","unstructured":"National Institute for Health and Care Excellence (NICE). Single Technology Appraisal \u2013 Appeal hearing: advice on mogamulizumab for previously treated mycosis fungoides and Sezary syndrome [ID1405]. Decision of the panel (2021). https:\/\/www.nice.org.uk\/guidance\/ta754\/history"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T15:26:15Z","timestamp":1695741975000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.57264\/cer-2023-0017"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0017","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"article-number":"e230017"}}